PAX8 and ovarian serous adenocarcinoma: The presented efficacy and safety data of the bivalent low affinity anti-LYPD1 TCB QZC131 directed against the PAX8 lineage-driven target LYPD1 supports its therapeutic potential and merits further evaluation as a treatment for advanced high-grade serous ovarian cancer.